Abnormality of amyloid-β precedes abnormality in tau, which leads to AD–related brain atrophy, [18F]-fluorodeoxyglucose (FDG) decline and accelerated cognitive decline [7]. The gene discussed is MAPT; the disease is Alzheimer disease.